Project Details
Description
The research project will determine the in vivo role of interleukin-1
receptor antagonist (IL-1ra) which is a naturally-occurring polypeptide
that bears 26% homology to IL-1Beta. By occupying the Interleukin-1 (IL-
1) receptor site, but failing to initiate the cellular response to IL-1,
IL-1ra may serve as an inhibitor of IL-1-mediated inflammatory processes.
Il-1ra has been shown to inhibit inflammatory responses when the
recombinant protein was administered to animals. In order to test
whether IL-1ra is an endogenous modulator of IL-1-related inflammatory
processes in vivo, mice will be genetically manipulated either to be
lacking the IL-1ra gene ('knockouts"), or having supernumerary copies of
it ("transgenics"). This will provide a tool in which the effect of
endogenous IL-1ra have been totally eliminated, or in which extra copies
may confer an additive effect of the gene product. Knockout and
transgenic mice will then be characterized in term of embryonic and fetal
development and tendency to the spontaneous occurrence of inflammatory
disorders. Susceptibility to inflammation will be tested by creating
three experimental models of inflammation and characterizing them in
transgenic and knockout mice: endotoxin-induced shock, monoarticular
(rheumatoid) arthritis and endometriosis.
Status | Finished |
---|---|
Effective start/end date | 2/1/93 → 1/31/98 |
Funding
- National Institute of Allergy and Infectious Diseases
ASJC Scopus Subject Areas
- Rheumatology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.